Drotaverine Injection in Pregnancy
Drotaverine injection can be used safely during pregnancy for labor augmentation and pain relief, with multiple studies demonstrating effectiveness in shortening labor duration without adverse maternal or fetal outcomes.
Evidence for Safety and Efficacy
The available evidence, while not from major international guidelines, comes from multiple clinical trials demonstrating drotaverine's safety profile in pregnancy:
Labor Augmentation Benefits
Drotaverine has been consistently shown to shorten the active phase of labor without compromising maternal or neonatal safety. A randomized, double-blind, placebo-controlled trial found that intravenous drotaverine (40mg) significantly reduced the mean duration of active labor from 8.33 hours (placebo) to 6.22 hours (drotaverine group), representing approximately 25% reduction 1. The cervical dilatation rate was significantly faster (1.68 cm/hr vs 1.06 cm/hr, p<0.001) 1.
Another large study of 320 nulliparous women confirmed these findings, showing drotaverine hydrochloride effectively shortened the first stage of labor with no difference in maternal adverse effects 2. Kaplan-Meier survival analysis demonstrated a significantly greater probability of faster delivery among patients treated with drotaverine 2.
Dosing Recommendations
Based on the research evidence:
- Standard dose: 40mg intravenously or intramuscularly
- Timing: Administered at the start of active labor (typically ≥3-4 cm cervical dilatation)
- Repeat dosing: Can be repeated every 1-2 hours for maximum of 3 doses 1, 2, 3
- Route: Both intravenous and intramuscular routes have been studied and found effective
Safety Profile
Multiple studies spanning nearly two decades have documented drotaverine's safety:
- No adverse fetal effects reported in controlled trials 4, 5
- No interference with uterine contractility 5
- No increase in operative delivery rates 5
- Minimal maternal side effects: Occasional headache reported, but significantly fewer side effects compared to alternative agents like valethamate bromide 3
One study noted increased atonic postpartum hemorrhage 4, though another found reduced incidence of traumatic postpartum hemorrhage by decreasing cervical tears 5. This discrepancy warrants monitoring for postpartum bleeding.
Maternal-Fetal Circulation Effects
A 2022 Doppler study evaluated drotaverine's effects on maternal and fetal circulation during the second and third trimesters 6. Oral drotaverine showed:
- No significant impact on umbilical artery or fetal middle cerebral artery pulsatility indices
- Statistically significant but clinically modest changes in uterine artery flow
- No adverse effects on fetal circulation parameters
This provides reassurance regarding drotaverine's vascular safety profile during pregnancy.
Important Caveats and Clinical Considerations
Lack of Major Guideline Support
A critical limitation is that drotaverine is not mentioned in major international obstetric or cardiovascular guidelines 7, 8, 9, 7, 10. The provided guidelines focus on antiarrhythmic drugs, antirheumatic medications, and cardiovascular management during pregnancy, but do not address antispasmodics like drotaverine.
The FDA drug label information provided 11 appears to reference propoxyphene (an opioid analgesic), not drotaverine, suggesting potential data confusion or mislabeling in the evidence base.
Regional Availability
Drotaverine is widely used in certain regions (particularly Eastern Europe, India, and parts of Asia) but may not be available in all countries. In regions where it's unavailable, alternative approaches to labor augmentation should be considered.
Monitoring Recommendations
When using drotaverine during labor:
- Monitor for postpartum hemorrhage given conflicting evidence
- Assess cervical dilatation progress regularly
- Monitor fetal heart rate patterns
- Watch for maternal side effects (headache, though rare)
- Consider that effectiveness may be greater in multiparous women and when administered at more advanced cervical dilatation 5
Clinical Algorithm for Use
If drotaverine is available and labor augmentation is desired:
- Confirm active labor (≥3-4 cm cervical dilatation with regular contractions)
- Administer 40mg drotaverine IV or IM
- Reassess cervical progress after 1-2 hours
- Repeat dose if needed (maximum 3 doses total)
- Monitor closely for postpartum hemorrhage after delivery
The evidence supports drotaverine as an effective and generally safe option for labor augmentation when used appropriately, though clinicians should be aware of the absence of major guideline endorsement and regional variations in availability and practice patterns.